188 related articles for article (PubMed ID: 25675382)
1. Successful treatment of type B insulin resistance with rituximab.
Manikas ED; Isaac I; Semple RK; Malek R; Führer D; Moeller LC
J Clin Endocrinol Metab; 2015 May; 100(5):1719-22. PubMed ID: 25675382
[TBL] [Abstract][Full Text] [Related]
2. Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies.
Malek R; Chong AY; Lupsa BC; Lungu AO; Cochran EK; Soos MA; Semple RK; Balow JE; Gorden P
J Clin Endocrinol Metab; 2010 Aug; 95(8):3641-7. PubMed ID: 20484479
[TBL] [Abstract][Full Text] [Related]
3. Type B Insulin Resistance in Peru.
Zelada H; Gamarra D; Arbañil H; Manrique H
Am J Med Sci; 2017 Mar; 353(3):258-262. PubMed ID: 28262212
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Mediated Extreme Insulin Resistance: A Report of Three Cases.
Kim HN; Fesseha B; Anzaldi L; Tsao A; Galiatsatos P; Sidhaye A
Am J Med; 2018 Jan; 131(1):102-106. PubMed ID: 28822702
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of insulin-like growth factor-1 in a patient with autoantibodies to insulin receptors: a case report.
Yamamoto T; Sato T; Mori T; Yamakita T; Hasegawa T; Miyamoto M; Hosoi M; Ishii T; Yoshioka K; Tanaka S; Fujii S
Diabetes Res Clin Pract; 2000 Jul; 49(1):65-9. PubMed ID: 10808065
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment with plasmapheresis, cyclophosphamide, and cyclosporin A in type B syndrome of insulin resistance. Case report.
Eriksson JW; Bremell T; Eliasson B; Fowelin J; Fredriksson L; Yu ZW
Diabetes Care; 1998 Aug; 21(8):1217-20. PubMed ID: 9702422
[TBL] [Abstract][Full Text] [Related]
7. Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study.
Klubo-Gwiezdzinska J; Lange M; Cochran E; Semple RK; Gewert C; Brown RJ; Gorden P
Diabetes Care; 2018 Nov; 41(11):2353-2360. PubMed ID: 30201849
[TBL] [Abstract][Full Text] [Related]
8. Systemic lupus erythematosus with acanthosis nigricans, hyperpigmentation, and insulin receptor antibody.
Baird JS; Johnson JL; Elliott-Mills D; Opas LM
Lupus; 1997; 6(3):275-8. PubMed ID: 9104736
[TBL] [Abstract][Full Text] [Related]
9. Diabetic Ketoacidosis Without Diabetes.
Willard D; Upadhyay J; Kim C; Steenkamp D
J Clin Endocrinol Metab; 2016 Nov; 101(11):3870-3873. PubMed ID: 27636019
[TBL] [Abstract][Full Text] [Related]
10. Novel Management of Insulin Autoimmune Syndrome with Rituximab and Continuous Glucose Monitoring.
Saxon DR; McDermott MT; Michels AW
J Clin Endocrinol Metab; 2016 May; 101(5):1931-4. PubMed ID: 26982011
[TBL] [Abstract][Full Text] [Related]
11. Continuous glucose monitoring and Rituximab treatment in insulin autoimmune syndrome.
Boro H; Gupta U; Singh C; Malhotra R; Khadgawat R
Diabetes Metab Syndr; 2021; 15(6):102294. PubMed ID: 34562871
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) with rituximab in a case refractory to glucocorticoids, cyclophosphamide, and IVIG.
Umezawa N; Kohsaka H; Nanki T; Watanabe K; Tanaka M; Shane PY; Miyasaka N
Mod Rheumatol; 2014 Jul; 24(4):685-7. PubMed ID: 24517553
[TBL] [Abstract][Full Text] [Related]
13. Hyperalimentation as cause of markedly worsened metabolic control in a patient with autoantibodies to the insulin receptor.
Vesely DL; Coleman MJ; Kohler PO; Jordan RM; Stanley S
Am J Med; 1985 Oct; 79(4):504-8. PubMed ID: 3931471
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
15. Case report: Successful combination therapy with double-filtration plasmapheresis and rituximab under the condition of the use of a sensor-augmented pump for type B insulin resistance syndrome.
Osanami A; Kanda M; Sato T; Akazawa C; Baba S; Komatsu H; Murase K; Yamashita T; Yano T
Front Endocrinol (Lausanne); 2022; 13():997296. PubMed ID: 36157458
[TBL] [Abstract][Full Text] [Related]
16. Insulin receptor antibodies and insulin resistance.
Magsino CH; Spencer J
South Med J; 1999 Jul; 92(7):717-9. PubMed ID: 10414483
[TBL] [Abstract][Full Text] [Related]
17. Management of epidermolysis bullosa acquisita.
Intong LR; Murrell DF
Dermatol Clin; 2011 Oct; 29(4):643-7. PubMed ID: 21925011
[TBL] [Abstract][Full Text] [Related]
18. Acquired hemophilia in the patient suffering from rheumatoid arthritis: case report.
Drobiecki A; Pasiarski M; Hus I; Sokołowska B; Wątek M
Blood Coagul Fibrinolysis; 2013 Dec; 24(8):874-80. PubMed ID: 24042266
[TBL] [Abstract][Full Text] [Related]
19. Type B Insulin Resistance Masquerading as Ovarian Hyperthecosis.
Brown RJ; Joseph J; Cochran E; Gewert C; Semple R; Gorden P
J Clin Endocrinol Metab; 2017 Jun; 102(6):1789-1791. PubMed ID: 27911591
[TBL] [Abstract][Full Text] [Related]
20. Regression of acanthosis nigricans correlates with disappearance of anti-insulin receptor autoantibodies and achievement of euglycemia in type B insulin resistance syndrome.
Fareau GG; Maldonado M; Oral E; Balasubramanyam A
Metabolism; 2007 May; 56(5):670-5. PubMed ID: 17445543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
